Patients undergoing new ureteral stenting for upper urinary tract stenosis stent-related symptoms, overactive bladder, ureteral stent
Conditions
Interventions
Vibegron group: Vibegron 50 mg will be administered orally once daily starting from the day of ureteral stent placement. The duration of administration will, in principle, correspond to the duration o
Administration, Oral
Sponsors
Hinata Nobuyuki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who will receive a new ureteral stent for upper urinary tract stenosis due to urinary lithiasis, malignancy, or transurethral lithotripsy (TUL) for urinary tract lithiasis 2) Patients who are 18 years of age or older at the time of consent 3) Patients who are able to complete the questionnaire 4) Patients who have been fully informed about their participation in this study, and who have given written consent of their own free will based on their full understanding of the study.
Exclusion criteria
Exclusion criteria: 1) Patients with bladder catheter in place prior to ureteral stenting 2) Patients with spinal cord paralysis or sensory insensitivity below the thoracic spinal cord 3) Patients with preoperative uncontrolled urinary tract infection 4) Patients with a diagnosis of dementia 5) Patients on medical therapy for benign prostatic hyperplasia 6) Patients on medical therapy for overactive bladder (OAB) 7) Patients on regular analgesic medication 8) Patients with a history of prior radiation therapy to pelvic organs 9) Patients undergoing bilateral ureteral stenting 10) Patients with serious cardiac disease or severe hepatic disorder 11) Patients with a history of hypersensitivity to any component of Vivegron 12) Other patients deemed inappropriate by the principal investigator or subinvestigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Change from baseline in Overactive Bladder Symptom Score (OABSS) at 2 weeks after ureteral stenting 2) Change from baseline in pain symptom scale (Visual analog scale: VAS) at 2 weeks after ureteral stenting | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Change from baseline in Overactive Bladder Symptom Score (OABSS) at the defined time point 2) Change from baseline in International Prostate Symptom Scor (IPSS) at the specified time point 3) Change from baseline in pain symptom scale (Visual analog scale: VAS) at defined time points 4) Number of analgesics (e.g., acetaminophen) 5) Percentage of adverse events | — |
Contacts
Public ContactYuki Kohada
Hiroshima University Hospital
Outcome results
None listed